- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02623127
A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma (KOSMIC)
A Phase II, Non-comparative, Open Label, Multi-center Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma
Study Overview
Detailed Description
Sunitinib (Sutent®; Pfizer, New York, NY, USA) is a multitargeted tyrosine-kinase inhibitor (TKI) with activity against the stem cell-factor receptor (KIT) and platelet-derived growth-factor receptor (PDGFR), vascular endothelial growth-factor receptor (VEGFR), glial cell line-derived neurotrophic factor receptor (rearranged during transfection [RET]), colony-stimulating factor-1 receptor (CSF1R), and Fms-like tyrosine kinase-3 receptor (FLT3).
Sunitinib is a potent inhibitor of mutant KIT with additional inhibitory effects on VEGF receptors that potentially might make it more effective than imatinib against TCs. In the current version of NCCN guideline, sunitinib is suggested as one of the potential targeted therapeutics for advanced TCs.
We planned this study to investigate the clinical efficacy and tolerability of sunitinib in patients with advanced or recurrent TCs in Korean population. In addition, we will collect tumor samples and blood samples from patients for the further exploration of predictive biomarkers.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Seongnam, Korea, Republic of, 463-707
- Seoul National University Bundang Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provision of signed, written and dated informed consent prior to any study specific procedures
- Histopathologically confirmed metastatic or recurrent thymic thymic carcinoma
- Age ≥ 20
- ECOG PS 0-2
- Documented progressive disease after one or more conventional systemic chemotherapy
- At least one measurable disease by RECIST v1.1
Adequate organ function for treatment as follows:
- Absolute neutrophil count > 1.5 x 109/L
- Platelets >100 x 109/L
- Serum creatinine ≤ 2.0 x ULN (upper limit of normal)
- Serum bilirubin ≤ 1.5 x ULN
- AST and ALT ≤ 2.5 x ULN (without liver metastasis), ≤ 5.0 x ULN (with liver metastasis)
- Life expectancy ≥ 12 weeks at day 1
Exclusion Criteria:
- Previous treatment with sunitinib or other VEGF-TKIs
- Any major operation or irradiation within 4 weeks of baseline disease assessment
- Any clinically significant gastrointestinal abnormalities which may impair intake or absorption of the study drug
- CNS metastasis with continuous corticosteroid use within 4 weeks of baseline disease assessment (Asymptomatic CNS metastasis patients can be enrolled)
- Patients with uncontrolled or significant cardiovascular disease (AMI within 12 months, Unstable angina within 6 months, NYHA Class III, IV Congestive heart failure or left ventricular ejection fraction below local institutional lower limit of normal or below 45%, Congenital long QT syndrome, Any significant ventricular arrhythmia, Any uncontrolled second or third degree heart block, Uncontrolled hypertension)
- Concomitant malignancy (except adequately treated basal cell cancer of skin or cervical cancer in situ)
- Female patients who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control
- Other severe acute or chronic medical condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the patient inappropriate for entry into this trial. (including active bleeding, untreated DVT or thromboembolism)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sunitinib
Sunitinib will be administered orally at a dose of 50 mg once daily in 3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate
Time Frame: Up to 6 months
|
CR or PR by RECIST criteria version 1.1
|
Up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease control rate
Time Frame: Up to 6 months
|
CR or PR or SD by RECIST criteria version 1.1
|
Up to 6 months
|
Progression-Free Survival
Time Frame: Up to 6 months
|
Up to 6 months
|
|
Overall survival
Time Frame: From first day of study treatment to day of any kind of death, assessed up to 24 months
|
From first day of study treatment to day of any kind of death, assessed up to 24 months
|
|
Incidence of treatment related adverse events [Safety and Tolerability]
Time Frame: Up to 6 months
|
Number of patients with adverse events during cycle 1 (each cycle is 21 days).
Subjects will be evaluated for toxicity according to NCI-CTCAE(Common Terminology Criteria for Adverse Events) of version 4.0.
|
Up to 6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biomarker endpoint
Time Frame: Day 1
|
When available, banked tumor tissue for genomic analysis for predictive biomarker of sunitinib.
|
Day 1
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jong Seok Lee, MD, PhD, Seoul National University Bundang Hospital
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Lymphatic Diseases
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Thoracic Neoplasms
- Neoplasms, Complex and Mixed
- Thymus Neoplasms
- Carcinoma
- Thymoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Protein Kinase Inhibitors
- Sunitinib
Other Study ID Numbers
- SNUBH-15-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thymic Carcinoma
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)Active, not recruitingUnresectable Thymic Carcinoma | Metastatic Thymic Carcinoma | Locally Advanced Thymic Carcinoma | Recurrent Thymic CarcinomaUnited States
-
Erasmus Medical CenterHospices Civils de Lyon; Maastro Clinic, The NetherlandsRecruitingThymic Carcinoma | Thymoma | Thymic Epithelial Tumor | Thymoma and Thymic CarcinomaNetherlands
-
Fudan UniversityRecruitingThymoma and Thymic CarcinomaChina
-
MedSIRMerck Sharp & Dohme LLCActive, not recruitingMetastatic Thymic Carcinoma | Thymoma Type B3Spain, France, Italy
-
Shanghai Chest HospitalRecruitingThymic Carcinoma | Thymic Epithelial Tumor | Thymic CancerChina
-
National Cancer Institute (NCI)CompletedThymic Carcinoma | Thymoma | Thymic Carcinoid | Thymic Neuroendocrine TumorsUnited States
-
Shanghai Pulmonary Hospital, Shanghai, ChinaRecruiting
-
Fudan UniversityCompletedThymoma and Thymic CarcinomaChina
-
Jian ChenRecruitingCarbon Ion Radiotherapy, Thymoma, Thymic Carcinoma, Radiotherapy, ChemotherapyChina
-
National Cancer Institute (NCI)TerminatedInvasive Thymoma and Thymic Carcinoma | Recurrent Thymoma and Thymic Carcinoma | Stage III Thymoma | Stage IVA Thymoma | Stage IVB ThymomaUnited States
Clinical Trials on Sunitinib
-
AGO Study GroupPhilipps University Marburg Medical Center; HSK Reasearch GmbH WiesbadenCompletedPlatinum Refractory Epithelial Ovarian Cancer | Primary Cancer of the Peritoneum | Cancer of the Fallopian TubeGermany
-
Mothaffar RimawiTerminated
-
Cogent Biosciences, Inc.RecruitingMetastatic Cancer | Advanced Gastrointestinal Stromal TumorsUnited States, Korea, Republic of, Spain, United Kingdom, Australia, France, Italy, Netherlands, Taiwan, Germany, Denmark, Hong Kong, Canada, Sweden, Norway, Mexico, Czechia, Argentina, Hungary, Brazil, Chile, Poland
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedKidney CancerUnited States
-
PfizerCompletedBreast NeoplasmsUnited States
-
PfizerCompletedGastrointestinal Stromal TumorsUnited States, Czechia, France
-
Asan Medical CenterCompletedMetastatic Renal Cell CarcinomaKorea, Republic of
-
PfizerCompletedGastrointestinal Stromal TumorsKorea, Republic of
-
California Pacific Medical Center Research InstitutePfizer; University of California, San FranciscoCompleted
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States